Strategic Performance Drivers
Delivered 11% revenue growth driven by the continued Essenz upgrade cycle and significant market share gains in cardiopulmonary consumables.
Cardiopulmonary market share increased from approximately 30% to 40% over the last two years, outperforming a mature market through execution and supply chain improvements.
Epilepsy performance was bolstered by the January 1, 2026, U.S. Medicare reimbursement increase, which raised hospital outpatient payments by approximately 47-48%.
Management noted that the updated reimbursement rates have reduced a historical economic barrier, improving realized pricing by allowing for reduced volume discounting.
Clinical evidence from the Core VNS study is actively reshaping clinician perceptions, leading to broader adoption within treatment algorithms for drug-resistant epilepsy.
Manufacturing output for oxygenators increased as third-party component availability improved, though demand continues to outpace the industry’s total supply capacity.
The company achieved FDA premarket approval for the aura6000 OSA system, notably without the concentric collapse contraindications found in competing devices.
Outlook and Strategic Initiatives
Raised full-year 2026 revenue guidance to 7% to 8% growth, reflecting stronger global acceptance of VNS therapy and improved cardiopulmonary output.
Expects Essenz to represent approximately 80% of annual heart-lung machine unit placements in 2026, up from 55% in 2025.
Planned manufacturing expansion includes a new production line in the second half of 2026 to drive low double-digit growth in oxygenator output.
The OSA commercial strategy targets a limited market release in the first half of 2027, followed by a broader launch in the second half of 2027.
Guidance assumes a $5 million headwind to operating income from Middle East conflict-related logistics costs and a similar $5 million impact from tariffs.
Risk Factors and Structural Updates
Capital spending is projected to reach $120 million in 2026, a $40 million increase over the prior year, to fund manufacturing scale-up and IT infrastructure.
Management views current ambiguity in the obstructive sleep apnea reimbursement market as temporary and expects the impact of GLP-1s to be net positive for the market.
The company repaid $98 million in outstanding term facilities early, reducing both cash and total debt balances at the end of the first quarter.
A competitor’s exit from the cardiopulmonary space is expected to provide further tailwinds for LivaNova’s market share expansion in consumables and hardware.
